Introduction: Thyroid hormone has a significant impact on every cell in the body by altering the rate of growth, cellular progression and differentiation, and the change in the levels of micronutrients, hormone stages, protein synthesis, lipids, and CHO. The connection between thyroid problems and blood coagulation systems was first mentioned scientifically at the beginning of the previous century. In patients with thyroid dysfunction, numerous acquired coagulation-fibrinolytic system abnormalities were studied. These deviations can range from minor lab anomalies to serious medical hemostatic dysfunction.
Aim of the study:To evaluate novel biomarkers as thrombosis predictors in thyroid dysfunction patients.
Subjects and Methods:This case-control study included 60 participants as follows; 20 patients in Group A, who have hyperthyroidism, have elevated thyroid functions, Group B contains 20 patients with hypothyroidism who have decreased thyroid function, and Group C consists of 20 individuals with normal thyroid function (the euthyroid group). Methods included taking a complete medical history (including OCPS use), age, gender, smoking, history of cancer, thromboembolic events, bleeding disorders, and thorough clinical examination. For lab tests and measurements of the CBC, PT, PTT, PC, TSH, FT4, D-dimer, and p-selectin level.
Results:The study groups did not differ significantly from one another regarding the PT-INR, PTT, and D-dimer levels, as well as the CBC components. Additionally, PTT and PLT count levels were significant predictors of pselectin levels.
Conclusion:It can be concluded that there was no significant variance among study groups concerning CBC components, PT-INR, PTT, and D-dimer level.